KRYS Krystal Biotech Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRYS
  4. Earnings
?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $7.75

Last Report Period Date: Mar 31, 2026

Based on the company's latest reports for March 2026, the current 12-month EPS is $7.75. Krystal Biotech's earnings per share in 2025 was reported at $7.08, marking a rise from $3.12 in 2024. In the quarterly report ending on Mar 31, 2026, KRYS's earnings per share amounted to $1.91.

KRYS earnings history

Historical annual and quarterly earnings per share (EPS) data for Krystal Biotech
EPS (TTM)
$7.75
EPS Growth YoY (Quarterly)
54%
EPS (Quarterly)
$1.91
EPS Growth (Quarterly)
7.9%

Krystal Biotech had an yealy earnings per share of $7.08, showing a rise of 126.9% from $3.12 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was $1.91, showing a 54% increase compared to the same quarter last year. The trailing twelve months EPS for KRYS is $7.75 as of March 2026. Krystal Biotech's full-year EPS for 2024 was $3.12, a 680% rise compared to the previous year.

KRYS earnings chart

KRYS EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
54%
EPS growth YoY
126.9%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Krystal Biotech has recorded a growth in earnings per share of 54% over the past 12 months (YoY, quarterly).

KRYS Earnings Waterfall

Breakdown of revenue, profit and net income for Krystal Biotech

KRYS Earnings vs Peers

What are the earnings of KRYS compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
VIVS VivoSim Labs Inc. 0.77 91.2% N/A N/A
ORMP Oramed Pharmaceuticals Inc 1.44 418.8% N/A N/A
OMER Omeros Corp 7.88 98.1% N/A N/A
KRYS Krystal Biotech Inc 39.67 126.9% N/A N/A
OLMA Olema Pharmaceuticals Inc N/A 15% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 19.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.